SenzaGen presents growth plan and strategic priorities at Capital Markets Day
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
SenzaGen is hosting its Capital Markets Day in Stockholm today, where CEO Peter Nählstedt, together with the management team and experts, provides deeper insights into the company’s strategic priorities and value-creation programs for profitable growth in non-animal testing. The upcoming strategic period lays the foundation for the next phase of the growth journey, enabling scalable and profitable expansion into new markets and product segments.
SenzaGen contributes to safer products in society – without sacrificing millions of animals. Through groundbreaking innovations, the company is realizing its vision to replace animal testing while protecting human health.
“SenzaGen is entering a very exciting phase, both in terms of new innovations and strong commercial development. Through focused sales efforts, we have built a solid platform with an established and recurring customer base and a fundamentally profitable business. We now aim to scale revenue and earnings by increasing efficiency and delivering initiatives that drive future growth. We also see opportunities for acquisitions to further accelerate development. I, together with the management team, look forward to sharing more about this,” says Peter Nählstedt, President and CEO.
To achieve this vision, the company has developed a plan divided into three phases, outlining the path for organic growth and development through 2030:
Phase 1: Break-even
The company currently assesses that it is in a break-even phase. During this period, the focus is on continuing to grow while maintaining strict cost control. Profitability is expected to gradually improve during this phase, strengthening financial stability.
Phase 2: Accelerated growth
Following the break-even phase, the company expects to enter an accelerated growth phase. This phase will be driven by the completion of ongoing strategic initiatives, including inclusion in the medical device ISO standard 10993, which is expected to have a significant positive impact on growth. These initiatives are projected to contribute approximately SEK 100 million in annual revenues within two years after completion, as previously communicated in connection with the 2024 capital raise. Profitability is also expected to increase significantly during this period as the business scales.
Phase 3: Scaling Up
The company expects to then enter a scaling phase. This phase will be enabled by new initiatives planned for launch and completion, with a particular focus on expansion in the U.S., FDA approval, and the introduction of new testing methods. During this phase, strong revenue growth is expected to continue, while profitability stabilizes at high levels, creating conditions for long-term and sustainable business development.
In addition to the organic growth plan, the company believes that strategic acquisitions can complement and strengthen growth across all phases, creating further opportunities to accelerate expansion and enhance value creation.
The Capital Markets Day will be webcast starting at 12:15 CET and can be followed via this link:
https://player.cybercaster.se/1681982681722/1761829008779